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Abstract

Other than CD4 + count, the immunologic factors that underlie the relationship of HIV/AIDS with persistent
oncogenic HPV (oncHPV) and cervical cancer are not well understood. Plasmacytoid dendritic cells (pDCs) and
regulatory T-cells (Tregs) are of particular interest. pDCs have both effector and antigen presenting activity and,
in HIV-positive patients, low pDC levels are associated with opportunistic infections. Tregs downregulate
immune responses, and are present at high levels in HIV-positives. The current pilot study shows for the first
time that low pDC and high Treg levels may be significantly associated with oncHPV persistence in both HIVpositive and HIV-negative women. Larger studies are now warranted.

mature and differentiate into dendritic cells (professional
antigen presenting cells) that are critical in initiating the
adaptive immune response through cognate interaction
with CD4 + T-cells (7). In vitro data show that pDCs can
respond to HPV antigens (10).
Tregs are involved in virtually all stages of the adaptive
immune response (see Fazekas de St Groth and Landay,
2008, for review) (5). This includes downregulation of
self-reactive immune cells, as well as the downregulation
of T cell responses to foreign antigens at the expansion and
effector stages. The mechanisms of action, though, remain
somewhat uncertain. It has been suggested that Treg activity may play a role in the establishment of the HIV
carrier state (3). The number of Tregs increases in the gut
during HIV infection, and high Treg ratios have been reported in patients with low CD4 + and high HIV RNA
levels (3,9). A small but growing literature suggests that
high levels of Tregs and cytokines associated with Treg
activity are more common in patients with HPV-related
cervical lesions (13–15,18).

Introduction

P

lasmacytoid dendritic cells (pDC) and regulatory
T-cells (Treg) may play an important role in HIV
pathogenesis and disease progression. However, their role
in the control of human papillomavirus (HPV), the viral
cause of cervical cancer, an AIDS-defining malignancy, has
not been carefully studied. pDCs are of particular interest,
since diminished pDC count and function are strongly
predictive of opportunistic infections in HIV-positive patients, independent of CD4 + T-cell count (19–21), and
imiquimod, a topically applied toll-like receptor (TLR)
agonist used to treat HPV-associated warts, may partly act
through activation of local pDCs (6). pDCs are unique in
that they bridge the innate and the adaptive immune systems (8,11). pDCs exist in the circulation and tissues as
effector cells of the innate immune system that secrete interferon (IFN)-a and other type I IFNs upon stimulation by
microbial pathogens. However, they are also precursor
cells, and following antigen interaction. they are thought to
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To our knowledge, however, no studies of oncogenic
HPV (oncHPV) infection and pDC levels have been reported, nor have the few prior studies of Tregs and HPV
involved HIV-positive women despite the known abnormalities of Treg and pDC levels and function among HIVpositive patients. Therefore, we conducted a small pilot
study to assess the relationship between pDC and Treg
levels in HIV-positive women and oncHPV persistence
(versus clearance). A smaller number of HIV-negative
women were included as an additional comparison group
and to obtain normal values.
Methods
Subjects and specimens

Data and specimens were obtained from the Women’s Interagency HIV Study (WIHS), a large prospective cohort investigation. A detailed summary of the WIHS and its methods
has been previously reported. Briefly, HIV-positive (n = 2543)
and at-risk HIV-negative (n = 895) women were followed
semiannually with clinical visits that involved a full gynecologic examination, including collection of a cervicovaginal
lavage (CVL) for HPV DNA testing. Blood specimens were
also collected and tested for total CD4 + T-cell count and HIV
RNA levels in laboratories participating in the DAIDS Quality
Assurance Program. Additional whole blood was collected in
sodium heparin-coated tubes and used to separate and cryopreserve peripheral blood mononuclear cells (PBMCs) using
standard, previously described methods (17).
For the current pilot study, we used stratified random sampling to select 19 ‘‘oncHPV persisters’’ and a comparison
group of 19 ‘‘oncHPV clearers.’’ We defined an oncHPV
persister as a woman who tested positive for at least one
oncHPV type, whether a prevalent or incident infection, who
then continued to test positive for one or more of the same
oncHPV types for ‡ 1.5 years (four semi-annual visits). An
oncHPV clearer was defined as a woman who tested positive
for at least one oncHPV type at the time of blood collection but
had no oncHPV at all detected at the next 6-month clinic visit.
We limited the selection of HIV-positive women to those with a
CD4 + > 350/lL, since it was felt that the contribution of pDC
and Treg levels to risk of persistent HPV might be difficult to
discern in women with a very low CD4 count. All women had
to have at least 2 years of follow-up (four visits plus baseline
visit) with no more than one missing visit. PBMC specimens
were available from 16 of the 19 oncHPV persisters (13 HIVpositive with a CD4 + > 350/lL and 3 HIV-negative women)
and 15 of the 19 oncHPV clearers (10 HIV-positive with a
CD4 + > 350/lL and 5 HIV-negative women).
HPV testing

HPV DNA was detected in CVL specimens using a wellestablished polymerase chain reaction (PCR) assay that
employed MY09/MY11/HMB01 consensus primers (16,22).
This assay has been shown to be highly sensitive and specific for the detection of > 40 different individual HPV types
(16). Amplification of a 268-base-pair fragment of the human b-globin gene was used as an internal control for
specimen adequacy. The HPV types considered oncogenic
were: 16/18/31/33/35/39/45/51/52/56/58/59/68, and all
other HPV were considered non-oncogenic.
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Flow cytometry

Flow cytometry for pDCs and Tregs was conducted twice
for each subject, once using cryopreserved PBMC specimens obtained at the first visit when oncHPV was detected
during this study, and again one year later. Briefly, the
cryopreserved PBMCs were removed from liquid nitrogen
(LN2) storage, thawed rapidly in a 37C water bath, washed,
and then incubated overnight at 37C 5% CO2 in RPMI
1640 media containing 10% heat-inactivated fetal bovine
serum (FBS). Following overnight incubation, the cells were
washed with Dulbecco’s PBS-(Ca + + Mg + + free) and stained
with Aqua Live/Dead cell stain kit (Invitrogen) to assess cell
viability. The PBMCs were then pre-treated with human Fc
block (Miltenyi Biotec) and stained for cell surface markers.
To assess pDCs, the PBMCs were incubated with the Lin1
FITC (BD), CD83 PE (Pharmingen), CD123 PerCP-Cy5.5
(Pharmingen), PDL-1 PE-Cy7 (eBioscience), CD11c AF700
(eBioscience), CD86 APC (Pharmingen), CCR7 eFluor780
(eBioscience), and HLA DR eFluor450 (eBioscience), washed
and resuspended in 2% formaldehyde-DPBS. To assess Tregs,
the PBMCs were stained with CD3 PacificBlue (Pharmingen),
CD4 PE-Texas Red (CalTag:Invitrogen), CD25 APC (BD),
CD45RO PE-Cy7 (BD), and PD-1 PE (eBioscience). Following surface staining, the Tregs were additionally washed,
fix/permeabilized with the FoxP3 Staining Buffer Set
(eBioscience), stained with FoxP3 FITC (eBioscience), and
CTLA-4 PE-Cy5 (Pharmingen), washed, and resuspended in
2% formaldehyde-DPBS. All stained cells were held at 4C
until acquired and analyzed within 24 h on a LSR2 flow
cytometer (BD) using FACS Diva 6.1.1 software (BD). The
analysis of flow cytometry data was performed after gating on
live (Aqua live dead) Lin1-yHLA DR + yCD123 + or
CD3 + yCD4 + yCD25 + yFoxP3 + cells corresponding to
pDC (% of PBMC) or Tregs (% of CD4), respectively.
Statistical methods

Analyses of these immunologic data were conducted using t-tests (for continuous variables), chi-square (for categorical or ordinal variables), as well as logistic regression
models to conduct multivariate analyses. Both pDC% and
Treg% were log transformed to normalize their distributions. All statistical tests were two-sided, and p < 0.05 was
used to define statistical significance.
Results

Table 1 shows selected patient characteristics and laboratory data in oncHPV persisters and clearers, stratified by HIV
serostatus. Mean age was approximately 37 years in HIVpositive and HIV-negative oncHPV persisters, and HIV-positive clearers, but was 33 years in HIV-negative clearers; a
moderate but statistically nonsignificant difference in this
small study. HAART use in HIV-positive women did not
significantly differ between persisters and clearers.
One of the selection criteria for HIV-positive women in
this study was a CD4 + > 350/lL, and neither the CD4 +
count ( p = 0.69) nor HIV viral load ( p = 0.27) differed between oncHPV persisters and clearers in univariate analyses
(Table 1). However, the percentage of CD4 + cells that were
found to be Tregs (Treg%) was significantly greater in HIVpositive oncHPV persisters than clearers ( p = 0.02), and
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Table 1. Selected Baseline Patient Characteristics and Laboratory Test Results in HIV-Positive
and HIV-Negative Women who Tested Positive for Oncogenic HPV,
Which then Either Persisted or Cleared
HIV-Positivea

Characteristic

oncHPV
Persistersb
(N = 13)

Age – SD
37.6 – 7.9
540 (42.40)*
Total CD4 count (SE)a
Mean Treg% (SE)
4.74% (0.38)
Mean pDC% (SE)
0.07% (0.02)
HIV RNA level
Undetectable
3 (23%)
Detectable
10 (77%)
HAART use in past 6 mo., No. (%)
No
6 (46.2)
Yes
7 (53.9)

oncHPV
Clearersc
(N = 10)

HIV-negative

P value

oncHPV
Persistersb
(N = 3)

oncHPV
Clearersc
(N = 5)

P value

37.3 – 5.2
579 (47.72)
3.22% (0.26)
0.09% (0.01)

0.91
0.81
0.02
0.12

37.2 – 9.5
1244 (250.12)*
5.97% (1.41)
0.05% (0.02)

32.5 – 15.8
1441 (652.50)
2.82% (0.18)
0.15% (0.03)

0.66
0.84
0.11
0.02

5 (50%)
5 (50%)

0.22

NA
NA

NA
NA

3 (30.0)
7 (70.0)

0.67

NA
NA

NA
NA

HAART, highly active anti-retroviral therapy; oncHPV, oncogenic HPV; Pdc, plasmacytoid dendritic cell; SD, standard deviation; SE,
standard error; Treg, regulatory T-cell.
*Significantly different between HIV-positive and HIV-negative persisters with p < 0.05.
a
The selection of HIV-positive women was limited to those with a CD4 count > 350 since it was felt that the impact of pDC% and Treg%
might be difficult to discern in women with a very low CD4 count. bAn oncHPV Persister was a priori defined as a subject who tested
positive for at least one oncHPV type at the time of blood collection and then continued to test positive for one or more of these exact
oncHPV types for ‡ 1.5 years. cAn oncHPV Clearer was a priori defined as a woman who tested positive for at least one oncHPV type at the
time of blood collection but had no oncHPV detected 6 months later, at the next clinic visit.

similar but nonsignificant Treg% results were found in HIVnegative women ( p = 0.11). Conversely, the percentage of
PBMCs that were pDCs (pDC%) was nonsignificantly lower
in HIV-positive oncHPV persisters than clearers (p = 0.12),
and a similar but statistically significant difference was
observed in HIV-negative women ( p = 0.02).
Multivariate models controlling for age and HAART use
were conducted in HIV-positive women. However, given
the similarity of the univariate findings in HIV-positive and negative subjects, we also conducted multivariate models
that incorporated the data from both groups (Table 2). As in
the univariate analysis, the positive Treg% association
( p = 0.05) but not the negative pDC% association with
oncHPV persistence ( p = 0.22) was statistically significant in
models limited to HIV-positive women. In the combined
analysis of HIV-positive and HIV-negative subjects, however, the statistical significance of the Treg% ( p = 0.01) and
pDC% ( p = 0.03) associations with oncHPV persistence was
greater, while HIV-serostatus was not a significant factor
( p = 0.81 in Treg% model, as well as in the pDC% model).
The confidence intervals for the effects of pDC% and Treg%
were wide, though, reflecting the small size of this pilot
study, making it inappropriate to conduct models involving
multiple immunologic covariates (e.g., incorporating both
Treg% and pDC% in the same model).
Discussion

The results of this pilot study suggest that a high Treg% and
low pDC% are each associated with increased risk of oncHPV
persistence. These findings are consistent with growing understanding of the role of Tregs in downregulating host immune response to pathogens (14), and the dual roles of pDCs
in the control of viral infection. pDCs are a-interferon-

secreting effector cells of the innate immune system with a
direct role in eliminating viral infection, but also act as antigen
presenting cells of the adaptive immune system, important in
the activation of T-cells (4,10). Furthermore, these associations were similar in both HIV-positive and HIV-negative
women. That is, while prior studies by our group and others
have shown that the risk of an oncHPV infection is severalfold higher in HIV-positive than HIV-negative women, the
current data suggest that Treg% and pDC% are risk factors for
the persistence of oncHPV in both groups (22).
Our data showing a positive association of Treg% with risk
of oncHPV persistence are consistent with prior reports (13–
15,18), though the current pilot study is, to our knowledge,
the first to examine this relationship in HIV-positive women.
Thus, while the number of studies is still small, the consistency of the findings regarding Tregs and oncHPV to date is
provocative. Conversely, the current study is the only one in
any population we are aware to examine the relation of
pDC% and oncHPV persistence, and these data must therefore be considered preliminary and await confirmation.
The findings of this study have potential clinical significance since they suggest that modulating Tregs and PDCs
may be a useful strategy to help resolve persistent oncHPV
or oncHPV related neoplasia. It is noteworthy, therefore,
that imiquimod, a topically applied toll-like receptor agonist
used to treat HPV-related anogenital warts can activate
pDCs (6). Imiquimod is not recommended for treatment of
cervical lesions however, due to local cervical toxicity,
likely attributed to the pro-inflammatory milieu induced by
imiquimod. If confirmed, our results would suggest that
additional efforts to target pDCs may be warranted. This
may be especially relevant now that cervical oncHPV DNA
testing is a routine part of cervical cancer screening, since
physicians and their patients are often left with the dilemma
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9
14

< 35
‡ 35

Age

ref
1.15

ref
0.72

0.74

OR

a

8
23
15
16

HIVHIV +

< 35
‡ 35

–

# of subjects

ref
1.13

ref
1.28

0.61

OR

6.99

4.69

1.18

Upper

0.21

0.18

0.39

Lower

6.11

9.04

0.96

Upper

95% CI

0.19

0.11

0.46

Lower

95% CI

0.89

0.81

0.03

P value

0.88

0.73

0.20

P value

< 35
‡ 35

No
Yes

9
14

9
14

–

# of subjects

ref
1.75

ref
1.90

5.29

OR

a

Age

HIV Statusc

log (Treg %)b

Variable

< 35
‡ 35

HIVHIV +

15
16

8
23

–

# of subjects

ref
1.37

ref
1.36

5.75

OR

a

(d) Tregs in HIV-positive and HIV-negative women

Age

HAART

log (Treg %)b

Variable

(c) Tregs in HIV-positive women

15.2

22.8

27.9

Upper

0.19

0.14

1.52

Lower

9.98

13.8

21.9

Upper

95% CI

0.20

0.16

1.00

Lower

95% CI

0.89

0.81

0.01

P value

0.61

0.61

0.05

P value

95% CI, 95% confidence interval; HAART, highly active anti-retroviral therapy; pDC, plasmacytoid dendritic cell; OR, odds ratio; Treg, regulatory T-cell.
a
pDC% and Treg% are both continuous variables and the p value is unaffected by the arbitrary choice of unit change chosen for presentation purposes in the table. Here we present ORs per 50%
increase in pDC% or Treg% (i.e., 0.4 unit increase on log scale).
b
Both pDC% and Treg% values were log transformed to normalize their distributions.
c
While oncogenic HPV persistence did not vary by HIV-positivitity, it must be noted that all HIV-positive women in this small pilot had CD4 > 350.

Age

HIV Statusc

log (pDC %)b

Variable

a

(b) pDCs in HIV-positive and HIV-negative women

9
14

No
Yes

–

# of subjects

HAART

log (pDC %)b

Variable

(a) pDCs in HIV-positive women

Table 2. Associations of Oncogenic HPV Persistence with Plasmacytoid Dendritic Cell (pDC) and Regulatorory T-Cell (Tregs)
Percentages Analyzed in Multivariate Models Among HIV-Positive Women (a, c) as Well as Using a Combined
Dataset of Both HIV-Positive and HIV-Negative Subjects (b, d)

24

of serial oncHPV positivity with no available methods to
eradicate oncHPV infection. Furthermore, local Treg and
pDC immunotherapy might be useful as adjuvants to reduce
the risk of recurrent cervical neoplasia, especially in HIVpositive and other high risk populations. It is also possible
that the relation of Tregs and pDCs with oncHPV persistence may play a role in the beneficial effects of HAART in
reducing oncHPV persistence observed in prior studies
(1,2,12). Larger and more comprehensive studies are
therefore warranted to expand upon the current observations, and better understand the effects of pDCs and Tregs
on HPV natural history.
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